New Products

Apr 05, 2017

UgenTec Interpretation Solution for PathoFinder PCR 2SMART Assays

UgenTec and PathoFinder have launched a cloud-based CE-IVD interpretation solution for PathoFinder's next generation multiplex PCR 2SMART assays. The solution uses UgenTect software to automate the interpretation of pathogens detected in PathoFinder's syndromic infectious disease panels. The solution has been rolled out to more than ten laboratories across Europe and the Middle East.

Apr 04, 2017

Strand Life Sciences StrandNGS v3.0

Strand Life Sciences has released version 3.0 of StrandNGS its flagship, next-generation sequencing data analysis and visualization platform. The firm has enhanced accuracy, precision, and speed. The new version also includes a "one shot pipeline execution option," improved RNA-Seq workflow processing speed, and full support for HGVS notation to support variant reporting and information exchange in DNA diagnostics.

Mar 31, 2017

Genetic Signatures EasyScreen STI/Genital Pathogen Detection Kit

Genetic Signatures has launched the EasyScreen STI Kit to simultaneously detect the 12 most commonly encountered sexually transmitted infections. The kit runs on standard lab equipment and the firm's proprietary 3base method, which reduces genetic information complexity and delivers accurate results in hours. The kit will initially be available for research use only until regulatory approvals are gained in Australia and the EU, and the 12 targets detected by the kit will also be available as analyte specific reagents in the US.

Mar 31, 2017

Swift Biosciences Accel Amplicon CFTR Panel and Accel-NGS XL Library Prep Kit

Swift Biosciences has launched the Accel Amplicon CFTR panel, which detects a wide range of variants and mutants in all exonic and select intronic regions of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. It produces sequence libraries in two hours, allows the user to process three to four times more libraries per day, and requires as little as 10 nanograms of sample input from either whole blood, dried blood spots, saliva, or buccal swabs.

The company has also launched the Accel-NGS XL Library Prep kit, which optimizes library preparation, particularly for the PacBio's Single Molecule, Real-Time SMRT sequencing. The kit provides longer sequencing reads with a single-tube workflow.

Mar 30, 2017

FlowJo SeqGeq

FlowJo has launched SeqGeq, a platform-agnostic desktop application for analysis of single-cell omics data. It offers tools to identify subpopulations of cells based on a variety of genes and synthetic parameters, to compare clusters and identify differentially-expressed genes or pathways of interest, and to generate publication-ready heatmaps and figures using a drag-and-drop layout editor. The application accepts a variety of data types, including scRNA-seq, RNA-Seq, and microarray data.

Mar 30, 2017

NanoString nCounter Enhancement Kits and Gene Expression Panels

NanoString has launched a new nCounter mRNA amplification kit, a universal cell capture kit, and two new nCounter assays. The nCounter Low RNA Input Kit employs multiplexed target enrichment to linearly amplify mRNA transcripts, enabling gene expression analysis with 1 nanogram to 10 nanograms of sample inputs. The kit is compatible with both pre-defined and custom panels. The Intracellular Compatible Universal Cell Capture Kit enables researchers to use the nCounter Vantage RNA:Protein Immune Cell Signaling Assay with as few as 20,000 cells. NanoString is also releasing two new assays. The RNA MAPK-PI3K Pathways panel provides a curated gene set to measure transcriptional activity of those pathways. The firm is also offering a gene expression panel for myeloid cell innate immune response in humans or mice, developed in partnership with Lisa Coussens of Oregon Health and Sciences University.

Mar 30, 2017

IncellDx OncoTect IO Lung Kit

IncellDx has launched the CE-IVD marked OncoTect iO Lung kit, a flow cytometry based assay. The kit incorporates a non-enzymatic single cell tissue homogenization process, using incellPREP, for unfixed tumor biopsy samples, labels cell suspensions with antibodies to CD45, CD8, CD3, PD-L1, stained with a Cell Cycle Dye, and then analyzes samples via flow cytometry. This allows researchers to enumerate the immune and tumor cell populations, quantify the percent of cells expressing PD-L1, and quantify PD-L1 receptor expression across each cell type. The assay also quantifies tumor infiltrating lymphocytes and quantification of PD-L1 expression at various stages of the tumor cell cycle.

Mar 30, 2017

Invitae Boosted Exome Sequencing and Interpretation Service

Invitae has launched an exome sequencing and interpretation service, called the Boosted Exome. Invitae believes this testing will be particularly useful in diagnosing rare pediatric diseases or providing insights into complex cases where doctors suspect a genetic disease but don't know which gene or alteration is involved. According to the company, the test analyzes 3 mL to 5 mL of whole blood (but can alternatively analyze saliva) and uses next-generation sequencing capture technology with boosted coverage of medically relevant genes. The exome test has the capability to analyze up to 20,000 protein coding genes, and also uses custom bioinformatics solutions for variant analysis, a phenotyping tool to prioritize relevant genes for analysis, and analytical solutions to identify other genes through inheritance patterns or functional impact. The data are interpreted by board-certified geneticists, and results are returned within six weeks to eight weeks. Parents have access to genetic counseling and doctors can confer with clinical consultants. Proband-only exome testing costs $2,500, while additional testing of one or both biological parents brings the cost up to $4,500.

Mar 29, 2017

Genomenon Mastermind Panel Design Service

Genomenon has launched its Mastermind Panel Design Service. The service provides researchers with genes and variants associated with a particular disease by using the company's Mastermind database to mine for disease-gene-variant relationships extracted from primary medical literature, the company said. Using that information, Genomenon researchers can help consumers curate a panel from candidate genes, exons, and variants supported by literature citation.

Mar 29, 2017

GeneNews BreastSentry

GeneNews has launched BreastSentry, a new risk stratification test for breast cancer. The company will offer the test in its Virginia-based clinical reference lab. The test measures the fasting plasma levels of two biomarkers in the blood, proneurotensin and proenkephalin, which are highly predictive of a woman's risk for developing breast cancer, the company said. It is intended for use in average risk women who have no family history of breast cancer, especially for women who have dense breast tissue, to better evaluate when patients may require further screening.

Mar 29, 2017

Empirical Bioscience Agarose Gel Extraction Kit

Empirical Bioscience has launched the Agarose Gel Extraction kit. The kit includes an extraction buffer, activation buffer, washing buffer, elution buffer, spin columns, and collection tubes. It allows efficient DNA purification from agarose gels and provides maximum recovery of DNA from 100bp to 10kb. It also removes primer-dimers, primers, nucleotides, proteins, salt, agarose, ethidium bromide, and other impurities, the company said.

Mar 29, 2017

Cellecta Driver-Map Human Genome-Wide Gene Expression Profiling Kit

Cellecta has launched its Driver-Map Human Genome-Wide Gene Expression Profiling kit. It is a multiplexed RT-PCR-based assay designed to easily provide a molecular "snapshot" of protein-coding genes from complex samples, starting from as little as 10 pg of total RNA. The assay includes a complete set of gene-specific and PCR-NGS primers, buggers, spike-in ERCC, positive control RNAs, and all other reagents required to profile 24 samples, the company said. The kit allows researchers to selectively amplify the 19,000 known annotated human transcripts, use experimentally validated GCA-rich primers for comprehensive view of the spectrum of gene regulation, and have exacting RNA quality control.

Mar 28, 2017

Personal Genome Diagnostics PlasmaSELECT 64

Personal Genome Diagnostics has launched the PlasmaSELECT 64, a targeted panel for pan-cancer tumor profiling that incorporates proprietary technologies and bioinformatics. It is the first liquid biopsy tumor profiling assay to test for microsatellite instability status, a biomarker for tumor mutational load that helps identify cancer patients who might benefit from checkpoint inhibitors and other immuno-oncology cancer therapies. The panel includes 15 unique biomarkers, 11 of which are associated with active clinical trials. The panel is enabled by the company's proprietary DNA extraction and sample preparation methods, which accommodate low-abundance cell-free DNA samples, as well as hybrid-capture processing in combination with high-coverage, next-generation sequencing. The company's proprietary VariantDx computational algorithms enable discrimination of sequencing artifacts and errors from bona-fide mutations.

Mar 28, 2017

SGI-DNA NGS Library Construction Kits

SGI-DNA has launched Next-Generation Sequencing Library Construction Kits for its BioXP 3200 system. The new kits allow scientists to prepare DNA samples for NGS applications on the BioXp 3200, which uses the Gibson assembly method, automating essential steps in reading and writing DNA on a single compact workstation.

Mar 28, 2017

Bruker Avance Neo NMR Research Platform

Bruker has launched its  Avance Neo NMR Research Platform. The next-generation NMR electronics console surpasses the firm's previous Avance III HD, offering even faster control, improved dynamic range, and enhanced flexibility and scalability, Bruker said. New transceiver architecture enables each channel of the Avance Neo to operate as a fully functional spectrometer. According to the company, the new system also allows NMR pulse programs developed on previous Avance platforms, as well as new multi-receive pulse sequencing and experimental design capabilities never before available in the field.

Mar 27, 2017

Bioline JetSeq DNA Quantification Kits

Bioline, a wholly-owned subsidiary of Meridian Bioscience, has launched the JetSeq Library Quantification Kit. The qPCR-based assay provides fast, accurate, and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina-compatible NGS libraries. The kit relies on SYBR Green for detection and contains all of the components required for library quantification, including dilution buffer, P5 and P7 adapter primers, and six pre-diluted DNA standards to minimize pipetting, reduce variability, and increase reproducibility. It has sufficient standards to quantify eighteen libraries on individual plates or up to seventy-six libraries when multiple libraries are quantified on the same plate.

Mar 27, 2017

10X Genomics Chromium Single Cell V(D)J Solution

10X Genomics has launched a high-throughput solution for profiling paired V(D)J transcripts from hundreds to millions of lymphocytes. The solution includes the necessary chemistry and microfluidics consumables, as well as a complete software suite, and it runs on the firm's Chromium Controller or Chromium Single Cell Controller microfluidics platforms. It will be useful to researchers in vaccine development, clonal immune cell dynamics, immune responses to checkpoint blockades, and the development of recombinant antibodies and engineered T cells used in immunotherapies for cancer and other diseases, the firm said. 

Mar 24, 2017

Cepheid Xpert MTB/RIF Ultra

Cepheid, Rutgers New Jersey Medical School and FIND launched the Xpert MTB/RIF Ultra test for diagnosing tuberculosis and resistance to the antibiotic rifampicin. The test is the second generation of Cepheid's Xpert MTB/RIF test, which was launched in 2010. The Ultra was redesigned to increase analytical sensitivity more than tenfold and to improve the detection of mutations associated with rifampin resistance, FIND said.

The World Health Organization recommends the new test be used as an alternative to the older test in all settings, but a WHO expert group also noted that because of the increased sensitivity, use of the Ultra can result in higher numbers of false positives, compared to Expert MTB/RIF. As a result, the group said more discussion is needed on implementing the new test and balancing increased sensitivity with decreased specificity in different settings.

The Ultra was developed by Cepheid in collaboration with Rutgers. Additional support was provided by the US National Institute of Allergy and Infectious Diseases, and FIND. The governments of Australia, the Netherlands, and the UK also provided funding. 

Mar 23, 2017

Seraseq Inherited Cancer DNA Mix Reference Material

SeraCare Life Sciences has launched multiplexed Seraseq Inherited Cancer DNA Mix reference material for inherited disease testing by next-generation sequencing. The mix is focused on seven genes associated with inherited cancer syndromes, including BRCA1 and BRCA2. It combines over 20 pathogenic variants of diverse types in well-characterized genomic background that can be used for assay development and analytical validation, the company said.

Mar 23, 2017

PierianDx Clinical Interpretation Services

PierianDx is launching clinical interpretation as part of its next-generation sequencing services portfolio. Customers will be able to select from a menu of options. Variant scientist review, conducted by PierianDx cancer biologists and genetics professionals, will provide variant classification and annotation. Medical director review, conducted by board-certified molecular pathologists and medical geneticists, will provide assessments of variants' medical significance, including recommended therapeutic options, disease monitoring, clinical trial enrollment, or genetic counseling. Options for direct consultation or participation on molecular tumor boards are also available. Sign-out services, conducted by PierianDx medical directors with the appropriate state licensures, will provide sign-out for cases previously reviewed by interpretation services.

Mar 23, 2017

Optra IPhronesis Knowledge Automation for Clinical Genomics Platform

Optra Health has launched iPhronesis Knowledge Automation for Clinical Genomics. The platform uses advanced natural language processing algorithms and deep machine learning in addition to the iPhronesis Cognitive Workbench to automate literature and data review. It includes data connectors to public databases, such ClinVar, and repositories, such as PubMed and OMIM. It includes an intuitive user interface and simple workflow so consumers can adopt the software quickly and efficiently, the company said.

Mar 23, 2017

Invitae Genetic Health Screen

Invitae has launched its Genetic Health Screen tests, an expansion of its offerings as part of the company's ongoing proactive genetic testing pilot program. The expansion includes additional genes linked to cancer, cardiovascular conditions and other genetic disorders and provides information on 139 medically actionable genes. The company also offers sub-panels focused only on cardiovascular conditions or cancer. The tests are intended for patients who do not meet diagnostic criteria for genetic testing, but who wish to use genetic information to help guide their health decisions, the company said. They can only be ordered by a physician.

Mar 23, 2017

Synthego CRISPRevolution Chemically Modified Synthetic sgRNAs

Synthego has announced new chemically modified synthetic single guide RNAs for CRISPR genome editing. The modified guides provide protection against intracellular immune responses in primary and stem cells and against exonuclease attack in both eukaryotic and prokaryotic cells. The sgRNAs are synthesized with 2'-O-methyl analogs and 3' phosphorothioate internucleotide linkages in the first three nucleotides at both the 5' and 3' end of the RNA molecule.

Mar 22, 2017

Genome Workbench 2.11.10

The National Center for Biotechnology Information has released Genome Workbench 2.11.10. This version of the platform includes critical improvement in HTTPs protocol communication with NCBI, improvements to the Graphical Sequence View, new manual for search in bio-trees, and numerous bug fixes and improvements.

Mar 22, 2017

Variantyx Genomic Intelligence Platform

Variantyx has launched its Genomic Intelligence platform. The platform automates the complete NGS testing process from sample collection to sequencing, data analysis, interpretation and clinical report generation. It utilizes public and the company's in-house resources to detect and report clinically actionable variants to consumers. The company is also offering to use the platform to review previously undiagnosed cases to provide a second opinion to clinicians at no cost, it said.

Pages

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.